GlobalData on MSN5d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
Monthly Prescribing Reference10d
Drugs in the Pipeline
IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...
Monthly Prescribing Reference10d
Diana Ernst, RPh
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk ...
Mena FN14d
Clover Announces Positive Clinical Data For RSV Vaccine Candidate SCB-1019 Compared Head-To-Head Versus GSK's AREXVY
"We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted AREXVY, indicating our potential best-in-class ...
Vietnam Investment Reviev14d
I-Mab to Participate at the Truist Securities BioPharma Symposium
I-Mab, a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will ...
MarketWatch14d
GSK Net Profit Expected to Rise, Turnover to Fall -- Earnings Preview
WHAT TO WATCH --VACCINES: Investors' concerns linger over sales expectations for the company's respiratory syncytial virus vaccine Arexvy and its best-selling shingles vaccine Shingrix for the ...
Eagle-Tribune14d
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
The 2023 approval of the world's first RSV vaccines in the US and Europe, GSK’s AREXVY and Pfizer’s ABRYSVO, was a significant milestone in addressing the grave unmet medical needs associated ...
pulmonologyadvisor14d
Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults
Preliminary data were announced from 2 clinical trials evaluating Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) in a broader population of adults at increased for RSV disease. Arexvy ...
Seeking Alpha16d
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...
Pharmabiz17d
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical ...
Business Insider17d
Graham Parry Recommends Sell Rating for GlaxoSmithKline Due to Concerns Over Arexvy Vaccine Efficacy and Safety
Graham Parry has given his Sell rating due to a combination of factors affecting GlaxoSmithKline’s Arexvy vaccine. The challenges highlighted include the limited effectiveness of a single shot ...
The Pharma Letter17d
New data for GSK’s Arexvy RSV vaccine
US pharma major GSK (LSE: GSK) yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine ... It’s part of the key information for keeping me informed ...